Abstract
Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Cardiovascular & Hematological Disorders-Drug Targets
Title: The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema
Volume: 7 Issue: 1
Author(s): Beate Rassler
Affiliation:
Keywords: nitric oxide (NO), high altitude pulmonary oedema (HAPE), capillary permeability, Acute respiratory distress syndrome (ARDS), right ventricular systolic pressure (RVSP), Inflammation, Cytokines
Abstract: Pulmonary oedema (PO) can emerge from mechanical disorders in pulmonary circulation leading to elevated fluid filtration in the lung, or from increased vascular permeability due to inflammatory or toxic injury of the alveolarcapillary barrier. A number of these disorders causing PO is associated with increased catecholamine (CA) levels in plasma and lung tissue and/or increased sympathetic activation such as neurogenic PO, high-altitude PO or PO in patients with phaeochromocytoma. Experimental CA stimulation in animals induced PO after less than one hour of infusion. Both α- and β-adrenergic mechanisms are involved in the pathogenesis but also in the resolution of PO. CAs increase pulmonary capillary pressure and thus, enhance fluid filtration into the pulmonary interstitium. Additionally, by activation of proinflammatory cytokines, they induce pulmonary inflammation that may lead to capillary leak. Finally, they play an important role in the regulation of alveolar fluid clearance. The present paper considers the pathways by which CAs contribute to the development of PO of various origin.
Export Options
About this article
Cite this article as:
Rassler Beate, The Role of Catecholamines in Formation and Resolution of Pulmonary Oedema, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152907780059038
DOI https://dx.doi.org/10.2174/187152907780059038 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
(Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry Hypertriglyceridemia: An Infrequent, Difficult-to-predict, Severe Metabolic and Vascular Problem Associated with Estrogen Administration
Current Vascular Pharmacology Vaccine Adjuvants: Key Tools for Innovative Vaccine Design
Current Topics in Medicinal Chemistry Cellular Therapy for Myocardial Repair
Current Cardiology Reviews An “Enigmatic” L-Carnosine (β-Alanyl-L-Histidine)? Cell Proliferative Activity as a Fundamental Property of a Natural Dipeptide Inherent to Traditional Antioxidant, Anti-Aging Biological Activities: Balancing and a Hormonally Correct Agent, Novel Patented Oral Therapy Dosage Formulation for Mobility, Skeletal Muscle Power and Functional Performance, Hypothalamic-Pituitary- Brain Relationship in Health, Aging and Stress Studies
Recent Patents on Drug Delivery & Formulation Increasing Neurogenesis with Fluoxetine, Simvastatin and Ascorbic Acid Leads to Functional Recovery in Ischemic Stroke
Recent Patents on Drug Delivery & Formulation Therapeutic Approach on AGE-RAGE Interaction and Its Function in Diabetic Inflammation Process
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Inflammatory Mechanisms in Atherosclerosis: The Impact of Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Anti-inflammatory Effects of Dietary Antioxidants
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Effect of Handgrip Exercise on QTc Interval During Different Phases of Menstrual Cycle
Vascular Disease Prevention (Discontinued) Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Analysis of Intoxication, Rehospitalization, and One-year Survival of Heart Failure Patients Receiving Digoxin at Harapan Kita National Cardiovascular Center, Jakarta, Indonesia: A Cross Section-observational Study
Current Drug Safety Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
Current Medicinal Chemistry Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System
Current Pharmaceutical Design Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Anesthesia for Bronchoscopy
Current Pharmaceutical Design